ReviewCurrent issues in molecular biology2025
The Gut Microbiota-Ferroptosis Axis: Emerging Perspectives in Gastrointestinal Tumorigenesis and Progression.
Review in Current issues in molecular biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, the relationship between the gut microbiota and gastrointestinal tumors has become a growing focus in tumor biology research. Ferroptosis, an iron-dependent form of programmed cell death, serves as a crucial link mediating the interaction between the two. This review begins by clarifying the intricate connections among the gut microbiota, ferroptosis, and gastrointestinal tumors. It then systematically summarizes the mediating role of ferroptosis, focusing on iron metabolism, lipid peroxidation, and amino acid metabolism, in facilitating host-microbiota interactions. From a metabolic standpoint, particular emphasis is placed on how the gut microbiota affects ferroptosis in various gastrointestinal tumors, including gastric, pancreatic, liver, and colorectal tumors, through the use of metabolites such as lipopolysaccharides (LPSs), short-chain fatty acids (SCFAs), bile acids (BAs), vitamins, glutamine (Gln), and tryptophan derivatives. A deeper understanding of this complex regulatory network reveals new mechanisms for the development and progression of digestive tract tumors. This insight could inform the development of novel therapeutic strategies targeting the gut microbiota-ferroptosis axis. Additionally, these findings point to the potential clinical value of pursuing this research direction.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.